MBIO News and Press, Mustang Bio Inc. From 04/30/19

NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

MICT (NASDAQ: MICT ) -29% . More news on: MICT, Inc., Micro Focus International plc, Precipio, Inc., Stocks on the move, , Read more ...

NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

- Biotech and healthcare stocks are loved by traders for their big price moves, which can happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and r...

Mustang Bio ( MBIO ) surged higher the prior week, after it highlighted substantially positive data in a phase 1/2 study using its gene therapy to treat patients with X-linked severe combined immunodeficiency ((XSCID)). It was shown that treatment with MB-107 was able to restore the immu...

Mustang Bio, Inc. ( MBIO ) soared last Thursday after the very successful results of its gene therapy, MB-107, for X-linked Severe Combined Immunodeficiency, or X-SCID, were published in the New England Journal of Medicine. The therapy, licensed from the St. Jude Children's Research Hospital, ...

Biotech Brief: Optimistic Outlook Growing for Multi-Billion Dollar Medical Device Industry April 23, 2019 Palm Beach, FL –April 23, 2019 – A recent industry article reported on an optimistic overview concerning the Medical Device Industry. It said: “The medical...

Yangtze River Port and Logistics (NASDAQ: YRIV ) -13% . More news on: Yangtze River Port and Logistics Limited, Mustang Bio, Inc., CannTrust Holdings Inc., Stocks on the move, , Read more ...

What an incredible two days it has been for Mustang Bio (NASDAQ:MBIO). On Wednesday, April 17, the company announced that it entered a licensing agreement with St. Jude Children’s Research Hospital to develop the lentiviral gene therapy to treat “bubble boy” disease. ...

Gainers : Mustang Bio (NASDAQ: MBIO ) +117% . Checkpoint Therapeutics (NASDAQ: CKPT ) +19% . Amyris (NASDAQ: AMRS ) +18% . Uxin (NASDAQ: UXIN ) +17% . Viomi Technology (NASDAQ: VIOT ) +16% . Fortress Biotech (NASDAQ: FBIO ) +15% . Broadwind Energy (NASDAQ: BWEN ) +13% . Libbey (NYSE...